SGD introduces Type 1 molded glass vials to portfolio

The offering is stratified into three tiers, AXess, AXecure and AXpert

SGD Pharma has added Type I molded glass vials to its service offering. The company has organised its parenteral Type I molded glass offer into three tailored value propositions: AXess, AXecure and AXpert – from which pharmaceutical manufacturers can choose, meeting drug product requirements and aseptic manufacturing constraints.

AXess delivers glass packaging with straightforward TCO and is designed for essential or primary care drugs that require inert Type I packaging. AXecure delivers more flexibility, with an entirely customisable offering, from glass vial design to palletisation options, SGD says.

AXpert is designed for the most demanding and costly drugs which require the highest level of quality and integrity, in applications such as oncology and specialty care. It also provides access to personalised support and service at all times.

The company says its analysis of parenteral market needs, including therapeutic applications, drug properties, and business environments, allows it to meet market demands for flexibility, quality assurance, and technical & regulatory support.

Camille Ermine, Product Manager Parenteral at SGD Pharma, explains: “We are one of the largest and most experienced manufacturers of Type I molded glass globally, thanks to our purpose-built facilities. Manufacturing excellence is at the heart of the three-tier offering. With the development of the AXess, AXecure and AXpert ranges, this portfolio elevates SGD Pharma’s existing products and services, delivering additional levels of security, product choice, support, and global availability to support Business Continuity.”

Companies